NCT03970954 - Low-dose Interleukin-2 in Women With Unexplained Miscarriages | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 5, 2021

Primary Completion Date

July 28, 2023

Study Completion Date

March 20, 2024

Conditions

Recurrent Miscarriage

Interventions

DRUG

low-dose IL-2

Subcutaneous injection of low dose of IL-2 for induction course of 5 days, the 10th day after the beginning of periods. At most 5 courses of low dose of IL-2.

Trial Locations (3)

75012

Mekinian, Paris

Kayem, Paris

75020

Bornes, Paris